SCHEMBL10134591

SCHEMBL10134591

CN1CCN(c2ccc(Nc3ccc(-c4ccc(C(N)=O)cc4)n4ccnc34)cc2F)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 2/20 0.46
BRD4 O60885 3/20 0.45
JAK1 P23458 2/20 0.45
FLT3 P36888 3/20 0.44
BTK Q06187 1/20 0.44
KDM4E B2RXH2 2/20 0.43
AXL P30530 2/20 0.42
CSF1R P07333 1/20 0.41
JAK2 O60674 2/20 0.41
RET P07949 1/20 0.41
ROS1 P08922 1/20 0.41
EML4 Q9HC35 1/20 0.41
ALK Q9UM73 1/20 0.41
WDR5 P61964 2/20 0.41
ALDH1A1 P00352 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1685218 0.91 MAPKAPK5 (0.44) MAPKAPK5BRD4JAK1FLT3BTK
SCHEMBL10134365 0.90 MAPKAPK5 (0.58) MAPKAPK5JAK2
SCHEMBL1674332 0.87 MAPKAPK5 (0.61) MAPKAPK5BRD4JAK1FLT3BTK
SCHEMBL1685153 0.86 MAPKAPK5 (0.61) MAPKAPK5JAK2ALK
SCHEMBL13922427 0.83 SMARCA2 (0.44) MAPKAPK5BRD4JAK1FLT3JAK2
SCHEMBL12618477 0.81 MAPKAPK5 (0.45) MAPKAPK5BRD4JAK1FLT3BTK
SCHEMBL10134367 0.80 MAPKAPK5 (0.64) MAPKAPK5JAK2
SCHEMBL12618516 0.80 HTT (0.46) MAPKAPK5JAK2L3MBTL1NPC1RAB9A
SCHEMBL1685198 0.79 MAPKAPK5 (0.48) MAPKAPK5FLT3BTKKDM4ECSF1R
SCHEMBL10134395 0.78 MAPKAPK5 (0.56) MAPKAPK5BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885BRD4 683/4885JAK1 1529/4885
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885BRD4 683/4885JAK1 1529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.